Steatorrhea surgery

Jump to navigation Jump to search

Steatorrhea Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Steatorrhea from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Steatorrhea surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Steatorrhea surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Steatorrhea surgery

CDC on Steatorrhea surgery

Steatorrhea surgery in the news

Blogs on Steatorrhea surgery

Directions to Hospitals Treating Steatorrhea

Risk calculators and risk factors for Steatorrhea surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Surgery is usually reserved for patients with refractory or pre-malignant complications, such as Enteropathy Associated T-cell Lymphoma (EATL) and ulcerative jejunitis (UJ). EATL patients presenting with ulcerative lesions, stenotic lesions, and perforation needs surgical intervention. Surgery also serves as a pre-therapy in order to prevent perforation of the small bowel during chemotherapy in case of EATL. After surgery patients receive immunotherapy, chemotherapy and/or stem cell transplantation.

Surgery

Surgery is usually reserved for patients with refractory or pre-malignant complications, such as Enteropathy Associated T-cell Lymphoma (EATL) and ulcerative jejunitis (UJ). EATL patients presenting with ulcerative lesions, stenotic lesions, and perforation needs surgical intervention. Surgery also serves as a pre-therapy in order to prevent perforation of the small bowel during chemotherapy in case of EATL. After surgery patients receive immunotherapy, chemotherapy and/or stem cell transplantation.[1][2][3]

References

  1. van de Water JM, Nijeboer P, de Baaij LR, Zegers J, Bouma G, Visser OJ, van der Peet DL, Mulder CJ, Meijerink WJ (2015). "Surgery in (pre)malignant celiac disease". World J. Gastroenterol. 21 (43): 12403–9. doi:10.3748/wjg.v21.i43.12403. PMC 4649123. PMID 26604647.
  2. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF (2010). "Surgically treated primary malignant tumor of small bowel: a clinical analysis". World J. Gastroenterol. 16 (12): 1527–32. PMC 2846261. PMID 20333796.
  3. Di Sabatino A, Biagi F, Gobbi PG, Corazza GR (2012). "How I treat enteropathy-associated T-cell lymphoma". Blood. 119 (11): 2458–68. doi:10.1182/blood-2011-10-385559. PMID 22271451.

Template:WS Template:WH